Your browser doesn't support javascript.
loading
Comparison of the clinical outcomes of patients with NSAID-exacerbated respiratory disease receiving aspirin or biologicals.
Tuncay, Gülseren; Damadoglu, Ebru; Cihanbeylerden, Melek; Can Bostan, Ozge; Kayikci, Hazal; Özer, Serdar; Karakaya, Gül; Kalyoncu, Ali Fuat.
Affiliation
  • Tuncay G; Division of Allergy and Clinical Immunology, Hacettepe University, Ankara, Turkey.
  • Damadoglu E; Division of Allergy and Clinical Immunology, Hacettepe University, Ankara, Turkey.
  • Cihanbeylerden M; Division of Allergy and Clinical Immunology, Hacettepe University, Ankara, Turkey.
  • Can Bostan O; Division of Allergy and Clinical Immunology, Hacettepe University, Ankara, Turkey.
  • Kayikci H; Division of Allergy and Clinical Immunology, Hacettepe University, Ankara, Turkey.
  • Özer S; Department of Otorhinolaryngology, Hacettepe University, Ankara, Turkey.
  • Karakaya G; Division of Allergy and Clinical Immunology, Hacettepe University, Ankara, Turkey.
  • Kalyoncu AF; Division of Allergy and Clinical Immunology, Hacettepe University, Ankara, Turkey.
J Asthma ; 60(10): 1885-1894, 2023 10.
Article in En | MEDLINE | ID: mdl-36971076
ABSTRACT

OBJECTIVE:

NSAID-exacerbated respiratory disease (NERD) is characterized by exacerbation of respiratory symptoms after NSAID intake. While research for specific treatment options continues in patients who cannot tolerate or are unresponsive to aspirin treatment after aspirin desensitization (ATAD), biologicals have emerged as a new therapeutic option in NERD patients. The aim of this study was to compare the quality of life, and the sinonasal and respiratory outcomes of NERD patients treated with ATAD or biologicals.

METHODS:

Patients who have been followed up at a tertiary care allergy center and who have been receiving at least one of ATAD, mepolizumab or omalizumab for at least six months were included. Evaluations were made using sinonasal outcome test (SNOT-22), asthma control test (ACT), short form-36 (SF-36), blood eosinophil counts, need for recurrent functional endoscopic sinus surgeries (FESS), and asthma or rhinitis exacerbations requiring oral corticosteroids (OCS).

RESULTS:

A total of 59 patients comprised of 35 (59%) females and 24 (41%) males with a mean age of 46.1 (min-max, 20-70) years were included. The baseline blood eosinophil count was higher, and a significant decrease in blood eosinophil counts was observed in the mepolizumab group compared to ATAD group (p = 0.001, p < 0.001, respectively). At follow-up, the rate of recurrent FESS was lower in the group that received mepolizumab (p = 0.02).

CONCLUSIONS:

In NERD patients, mepolizumab significantly decreased blood eosinophil counts and recurrent FESS. There was no significant difference between the patients receiving ATAD or mepolizumab regarding other clinical parameters.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Asthma / Biological Products Type of study: Diagnostic_studies Aspects: Patient_preference Limits: Female / Humans / Male / Middle aged Language: En Journal: J Asthma Year: 2023 Document type: Article Affiliation country: Turkey

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Asthma / Biological Products Type of study: Diagnostic_studies Aspects: Patient_preference Limits: Female / Humans / Male / Middle aged Language: En Journal: J Asthma Year: 2023 Document type: Article Affiliation country: Turkey